|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI
|
|
2
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB,
Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al:
Efficacy and safety of nivolumab plus ipilimumab in patients with
advanced hepatocellular carcinoma previously treated with
sorafenib: The CheckMate 040 Randomized clinical trial. JAMA Oncol.
6:e2045642020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yau T, Park JW, Finn RS, Cheng AL,
Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, et
al: Nivolumab versus sorafenib in advanced hepatocellular carcinoma
(CheckMate 459): A randomised, multicentre, open-label, phase 3
trial. Lancet Oncol. 23:77–90. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
No authors listed. Correction to Lancet
Oncol. 2021.22:977–90. Lancet Oncol. 22:e3472021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang Y, Mu H and Zhao H: HMBOX1, a member
of the homeobox family: Current research progress. Cent Eur J
Immunol. 48:63–69. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen S, Li Y, Zhi S, Ding Z, Wang W, Peng
Y, Huang Y, Zheng R, Yu H, Wang J, et al: WTAP promotes
osteosarcoma tumorigenesis by repressing HMBOX1 expression in an
m(6)A-dependent manner. Cell Death Dis. 11:6592020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu YL, Diao NN, Li YZ, Meng XH, Jiao WL,
Feng JB, Liu ZP and Lu N: Low expression level of HMBOX1 in
high-grade serous ovarian cancer accelerates cell proliferation by
inhibiting cell apoptosis. Biochem Biophys Res Commun. 501:380–386.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Diao N, Li Y, Yang J, Jin C, Meng X, Jiao
W, Feng J, Liu Z and Lu N: High expression of HMBOX1 contributes to
poor prognosis of gastric cancer by promoting cell proliferation
and migration. Biomed Pharmacother. 115:1088672019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao H, Jia H, Han Q and Zhang J: Homeobox
containing 1 inhibits liver cancer progression by promoting
autophagy as well as inhibiting stemness and immune escape. Oncol
Rep. 40:1657–1665. 2018.PubMed/NCBI
|
|
11
|
Coronell-Tovar A, Pardo JP,
Rodriguez-Romero A, Sosa-Peinado A, Vasquez-Bochm L, Cano-Sanchez
P, Alvarez-Anorve LI and Gonzalez-Andrade M: Protein tyrosine
phosphatase 1B (PTP1B) function, structure, and inhibition
strategies to develop antidiabetic drugs. FEBS Lett. 598:1811–1838.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Monoe Y, Jingushi K, Kawase A, Hirono T,
Hirose R, Nakatsuji Y, Kitae K, Ueda Y, Hase H, Abe Y, et al:
Pharmacological Inhibition of miR-130 family suppresses bladder
tumor growth by targeting various oncogenic pathways via PTPN1. Int
J Mol Sci. 22:47512021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jin T, Li D, Yang T, Liu F, Kong J and
Zhou Y: PTPN1 promotes the progression of glioma by activating the
MAPK/ERK and PI3K/AKT pathways and is associated with poor patient
survival. Oncol Rep. 42:717–725. 2019.PubMed/NCBI
|
|
14
|
Xu Q, Wu N, Li X, Guo C, Li C, Jiang B,
Wang H and Shi D: Inhibition of PTP1B blocks pancreatic cancer
progression by targeting the PKM2/AMPK/mTOC1 pathway. Cell Death
Dis. 10:8742019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YJ, Song H, Yoon YJ, Park SJ, Kim SY,
Cho Han D and Kwon BM: Ethacrynic acid inhibits STAT3 activity
through the modulation of SHP2 and PTP1B tyrosine phosphatases in
DU145 prostate carcinoma cells. Biochem Pharmacol. 175:1139202020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie L, Qi H, Tian W, Bu S, Wu Z and Wang
H: High-expressed PTPN1 promotes tumor proliferation signature in
human hepatocellular carcinoma. Heliyon. 9:e198952023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng LY, Zhou DX, Lu J, Zhang WJ and Zou
DJ: Downregulated expression of the protein-tyrosine phosphatase 1B
(PTP1B) is associated with aggressive clinicopathologic features
and poor prognosis in hepatocellular carcinoma. Biochem Biophys Res
Commun. 420:680–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47((W1)): W556–W560.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gyorffy B: Integrated analysis of public
datasets for the discovery and validation of survival-associated
genes in solid tumors. Innovation (Camb). 5:1006252024.PubMed/NCBI
|
|
20
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10:15232019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szklarczyk D, Kirsch R, Koutrouli M,
Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT,
Pyysalo S, et al: The STRING database in 2023: Protein-protein
association networks and functional enrichment analyses for any
sequenced genome of interest. Nucleic Acids Res. 51((D1)):
D638–D646. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
de Bruijn I, Kundra R, Mastrogiacomo B,
Tran TN, Sikina L, Mazor T, Li X, Ochoa A, Zhao G, Lai B, et al:
Analysis and visualization of longitudinal genomic and clinical
data from the AACR project GENIE biopharma collaborative in
cBioPortal. Cancer Res. 83:3861–3867. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rauluseviciute I, Riudavets-Puig R,
Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, Lemma RB,
Lucas J, Cheneby J, Baranasic D, et al: JASPAR 2024: 20th
anniversary of the open-access database of transcription factor
binding profiles. Nucleic Acids Res. 52((D1)): D174–D182. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du J, Yu X, Zhang W, Zhang X, Zhao H, Xu R
and Wen Q: Plasma biomarker screening based on proteomic signature
of patients with resistant hypertension. j Cardiovasc Transl Res.
17:1286–1294. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mroweh M, Roth G, Decaens T, Marche PN,
Lerat H and Macek Jilkova Z: Targeting Akt in hepatocellular
carcinoma and its tumor microenvironment. Int J Mol Sci.
22:17942021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paskeh MDA, Ghadyani F, Hashemi M,
Abbaspour A, Zabolian A, Javanshir S, Razzazan M, Mirzaei S,
Entezari M, Goharrizi MASB, et al: Biological impact and
therapeutic perspective of targeting PI3K/Akt signaling in
hepatocellular carcinoma: Promises and Challenges. Pharmacol Res.
187:1065532023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao Y and Hung MC: Physiological
regulation of Akt activity and stability. Am J Transl Res. 2:19–42.
2010.PubMed/NCBI
|
|
28
|
Chen C, Xu R, Guo C, Li X, Zhao Y and Luo
D: Lanostane triterpenoids from Ganoderma calidophilum exhibit
potent antitumor activity by inhibiting PTP1B. Chem Biol Interact.
403:1112532024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li H, Dusseault J and Larose L: Nck1
depletion induces activation of the PI3K/Akt pathway by attenuating
PTP1B protein expression. Cell Commun Signal. 12:712014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dai J, Zhang C, Tian Z and Zhang J:
Expression profile of HMBOX1, a novel transcription factor, in
human cancers using highly specific monoclonal antibodies. Exp Ther
Med. 2:487–490. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu L, Wei J and Liu P: Attacking the
PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment
in human cancer. Semin Cancer Biol. 85:69–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chiarugi P and Buricchi F: Protein
tyrosine phosphorylation and reversible oxidation: Two
cross-talking posttranslation modifications. Antioxid Redox Signal.
9:1–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Jong PR, Takahashi N, Harris AR, Lee J,
Bertin S, Jeffries J, Jung M, Duong J, Triano AI, Lee J, et al: Ion
channel TRPV1-dependent activation of PTP1B suppresses
EGFR-associated intestinal tumorigenesis. J Clin Invest.
124:3793–3806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu S, Bjorge JD and Fujita DJ: PTP1B
contributes to the oncogenic properties of colon cancer cells
through Src activation. Cancer Res. 67:10129–10137. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lessard L, Stuible M and Tremblay ML: The
two faces of PTP1B in cancer. Biochim Biophys Acta. 1804:613–661.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan F, Gao Q, Tang H, Shi J and Zhou Y:
Ophiopogonin-B targets PTP1B to inhibit the malignant progression
of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK
signaling pathways. Mol Med Rep. 25:1222022. View Article : Google Scholar : PubMed/NCBI
|
